Oslo, Norway, 11 October 2016 - Serodus ASA (OSE: SER): Reference is made to the stock exchange notice on September 30th, 2016. Management has tested the interest for delisting Serodus from the Oslo Stock Exchange by having discussions with central shareholders. As part of these discussions the main owner of Serodus has indicate a willingness to give a voluntary offer of NOK 1.30 per share provided that a significant part of the share capital is willing to maintain their ownerships and continue to support the company in the delisting process.

At the current moment 69.9 % of the share capital has given their support to the ongoing delisting process. The majority shareholder together with management, has decided to prolong the timeline in order to verify whether it is possible to increase the level support additionally.

For more information, please consult www.serodus.com or contact:

Tore Kvam

CFO, Serodus ASA

Mobile: +47 959 34 199

e-mail: tore.kvam@serodus.com

Serodus ASA is a Norwegian drug development company, focusing on new therapeutic products for the treatment of diabetes and diabetic comorbidities with large unmet clinical needs. The company's business model is to seek partnering with international pharmaceutical companies after having demonstrated clinical effect in humans. For more information, see www.serodus.com.

Serodus ASA published this content on 11 October 2016 and is solely responsible for the information contained herein.
Distributed by Public, unedited and unaltered, on 22 October 2016 11:23:01 UTC.

Original documenthttp://www.serodus.com/News/2016/Evaluating-financing-model-prolonging-timeline

Public permalinkhttp://www.publicnow.com/view/4ABDE3FE134B66BC4A9A1BAE687775718FF8725A